This was similar to the results of Keane, who showed that DLBCL patients had high LAG-3 expression in TILs, along with enrichment of PD-1 and TIM-3, and that high LAG-3 gene expression was associated with low survival in the cohort (25). This evidence concerns the gene HAVCR2 and diffuse large B-cell lymphoma.